Connect with us

Life Sciences

Viz.ai Partners with Us2.ai to Deliver AI-Enabled Echocardiography Decision Support with the Viz Platform

Partnership delivers critical insights to cardiac care teams for faster patient triage and care Viz.ai, the leader in AI-powered disease detection and…

Published

on

This article was originally published by AITHORITY
Viz.ai Partners with Us2.ai to Deliver AI-Enabled Echocardiography Decision Support with the Viz Platform

Partnership delivers critical insights to cardiac care teams for faster patient triage and care

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, announced it has partnered with Us2.ai, the developer of AI software that fully automates a complete echocardiography, or heart ultrasound, report. Under the partnership, Viz.ai will offer Us2.ai’s FDA-cleared and CE Marked echocardiogram viewing and measurement tools with the Viz Platform to improve and speed the coordination of care for patients with suspected heart disease, the leading cause of death worldwide.

Browse The Complete News About Blockchain : Blockchain Partnership: PraSaga and Metahug Gamify Web3 Education Via Roblox

“Viz.ai is a natural partner for Us2.ai given the proven success of its care coordination platform and its vast network covering 200 million lives”

“Echo is an essential tool in the delivery of cardiovascular care. We believe that no heart disease patient should have to wait for care when time is critical,” said Chris Mansi, CEO of Viz.ai. “The average time to complete an echo takes up to 60[1] minutes, plus additional reporting time. Using AI can dramatically reduce this time burden, as well as ensure a uniform standard of excellence in reporting. We are proud to partner with Us2.ai to enhance and complement our comprehensive AI platform, tailoring it to cardiovascular needs, so that cardiologists and care teams can provide optimal care to more patients most efficiently.”

Data to Power BI : 3 Ways to Export ServiceNow Data to Power BI

The partnership with Us2.ai expands Viz.ai’s leadership in the cardiovascular arena, where the company also has FDA-cleared AI modules for cryptogenic stroke, aortic disease, and pulmonary embolism with an automated right ventricle/left ventricle (RV/LV) ratio algorithm. Us2.ai’s technology is a patented, automated clinical workflow solution that recognizes and analyzes 2D and Doppler echo images for comprehensive cardiac measurements needed for the diagnosis, prediction and prognosis of heart disease and pulmonary hypertension. Us2.ai produces complete echo reports in less than 2 minutes.[2] The Viz Platform with Us2.ai’s technology will help decrease the time from patient admission to treatment by expediting clinician access to echocardiogram reports and increasing patient access to time-critical diagnostics in the acute and post-acute care phases.

“Viz.ai is a natural partner for Us2.ai given the proven success of its care coordination platform and its vast network covering 200 million lives,” said Seth Koeppel, head of business development at Us2.ai. “With a national shortage of sonographers, the combination of our leading-edge applications will support hospitals and providers as well as patients. We look forward to bringing the power of our AI-enabled cardiovascular solution to more cardiac care teams and patients across the U.S.”

Next-gen AI-On-Demand Platform :  European Commission Pumps in $9.15 Million to Develop Next-gen AI-On-Demand Platform

[To share your insights with us, please write to sghosh@martechseries.com] 

The post Viz.ai Partners with Us2.ai to Deliver AI-Enabled Echocardiography Decision Support with the Viz Platform appeared first on AiThority.

diagnostics

Markets

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending